Curis Q1 net loss narrows to $11.6M; enrolls 9 patients for emavusertib; new CDO

CURIS INC

2023-Q1 EPS reported -$0.12 revenue$2,297,000

Net loss $11.6M ($0.12/share) vs $16.1M ($0.18) YoY; revenue $2.3M, up from $2.1M.
Enrolled 9 additional patients at 200mg BID for emavusertib; FDA partial clinical hold discussion expected in Q3 2023.
Appointed Jonathan Zung, Ph.D. as Chief Development Officer effective May 1, 2023; previously CDO at Evelo.
Cash and investments $71.8M as of Dec 31, 2022; cash runway expected into 2025.
R&D expenses down to $9.1M from $11.4M; G&A down to $4.8M from $5.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CURIS INC reported the first quarter ended March 31, 2023 results: revenue $2.3 million, net income a net loss of $11.6 million, EPS $0.12 per share on both a basic and diluted basis.

Period: the first quarter ended March 31, 2023
Revenue: $2.3 million
Net income: a net loss of $11.6 million
EPS: $0.12 per share on both a basic and diluted basis
Result: reported results

Exact text from the filing

and diluted basis as compared to $16.1 million or $0.18 per share on both a basic and diluted basis, for the same period in 2022. Revenues for the first quarter of 2023 were $2.3 million as compared to $2.1 million for the same period in 2022. Revenues for both periods consist of royalty revenues from Genentech's and Roche's sales of Erivedge®. Research and

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

CURIS INC filing history →

Source: SEC EDGAR

accession 0001108205-23-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.